Whats next for inotuzumab ozogamicin in ALL?

The anti-CD22 antibody-drug conjugate inotuzumab ozogamicin was approved for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL), the most common form of ALL, based on data from the I... Author: VJHemOnc Added: 02/20/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts